Business
Microbix Hires Dr. Andre Uddin of BioStrategy Management
Microbix Hires Dr. Andre Uddin of BioStrategy Management.
About this update from Microbix Biosystems Inc.
[{"type":"text","content":"\n\n\n\nTORONTO, Sept. 28 /CNW/ - Microbix Biosystems Inc. (TSX:MBX) announced\ntoday that Dr. Andre Uddin, President of BioStratgy Management Inc. has been\nhired to evaluate new strategic initiatives and help build shareholder value.\nThis partnership was formed in an effort to enhance Microbix's relationships\nwith the institutional investment community. "We are excited to have Dr. Uddin\non board as we enter the next growth phase for Microbix," commented William J.\nGastle, Chairman and CEO of Microbix, "BioStrategy Management will enhance our\nability to communicate our unique message to the institutional community as we\nfocus on forming strategic alliances to get our innovative products to\nmarket."\n\n\nDr. Uddin, was a top ranked analyst specializing in coverage of the\nCanadian biotechnology, pharmaceutical and medical device sectors. Dr. Uddin\nhas held senior biotechnology and pharmaceutical analyst positions at National\nBank Financial, Research Capital and Merrill Lynch Canada. Dr. Uddin holds an\nHonours Bachelor of Science (B.Sc.) degree in BioChemistry from the University\nof Toronto and a Doctor of Philosphy (Ph.D.) in Biological Chemistry from\nMcGill University.\n\n\n"The management team of Microbix has built a solid company which I\nbelieve has the potential to join the Canadian list of elite biotechnology\ncompanies that are profitable. What is unique to Microbix is that the\ncompany's base business has been generating a steady stream of cash flow\nproviding a platform to help finance its large market products. All three of\nthese products are approaching commercialization with growing partnering\ninterest. Given this promising outlook, BioStrategy Management looks forward\nto helping build shareholder value for Microbix," said Dr. Andre Uddin.\n\n\nThe Company's major pipeline products include: its VIRUSMAX(TM)\nTechnology which significantly boosts the yield of influenza virus from eggs\nand can help address the current global flu vaccine capacity issue; Urokinase,\na thrombolytic biologic that can be used as a catheter clearing drug and has\npotential in new cancer drug combination; and its Semen Sexing Technology(TM)\nwhich can ensure the sex of livestock offspring resulting from artificial\ninsemination.\n\n\n"With his ten years of extensive capital market experience ...